Riquent Trial Fails; Is This La Jolla’s Last Gasp?
This article was originally published in The Pink Sheet Daily
Executive Summary
Data monitoring board says continuing ASPEN trial is “futile” after first interim look at BioMarin-licensed Riquent trial for treatment of lupus nephritis.